Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service

Abstract

In contrast to overanticoagulation, evidence on risk factors and outcome of subtherapeutic oral anticoagulation (OAC) with vitamin K-antagonists (VKAs) under optimum care is limited. We investigated the clinical phenotype, anticoagulation control, and clinical outcome of 760 VKA patients who received OAC therapy by a specialized coagulation service in the thrombEVAL study (NCT01809015). During 281,934 treatment days, 278 patients experience ≥ 1 episode of subtherapeutic anticoagulation control and had lower quality of OAC therapy compared to 482 patients without subtherapeutic international normalized ratio: 67.6%, interquartile range (IQR) 54.9%/76.8% versus 81.0%, IQR 68.5%/90.4%; p < 0.001. In Cox regression analysis with adjustment for age, sex, cardiovascular risk factors, comorbidities, and treatment characteristics, female sex (hazard ratio [HR], 1.4, 95% confidence interval [CI], 1.0/1.9; p = 0.03), diabetes (HR, 1.4, 95% CI, 1.0/2.0; p = 0.03), and living alone (HR, 1.5, 95% CI, 1.1/2.1; p = 0.009) were independent risk factors of subtherapeutic anticoagulation control, whereas atrial fibrillation (HR, 0.6, 95% CI, 0.4/0.9; p = 0.02) and self-management of OAC therapy (HR, 0.2, 95% CI, 0.1/0.6; p = 0.001) were protective. In addition, active smoking (HR, 1.7, 95% CI, 0.9/3.0; p = 0.086) and living in a nursing home (HR, 1.6, 95% CI, 0.8/3.2; p = 0.15) indicated an elevated risk at the borderline of statistical significance. For the prediction of recurrent subtherapeutic anticoagulation, living alone was the only independent risk factor (HR, 1.7, 95% CI, 1.1/2.5; p = 0.013). The present study suggests that women, diabetics, and patients living alone experience an increased risk of low-quality VKA therapy and might potentially benefit from treatment with direct-acting anticoagulants.

Keywords

oral anticoagulation - vitamin K-antagonists - subtherapeutic INR - risk factors

• References

• 1 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 160s-198s
• 2 Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127 (05) 1515-1522
• 3 Prochaska JH, Göbel S, Keller K. , et al. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. BMC Med 2015; 13: 14
• 4 Reynolds MW, Fahrbach K, Hauch O. , et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Chest 2004; 126 (06) 1938-1945
• 5 Samsa GP, Matchar DB, Goldstein LB. , et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160 (07) 967-973
• 6 Holbrook A, Schulman S, Witt DM. , et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e152S-184S
• 7 Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335 (08) 540-546
• 8 Rombouts EK, Rosendaal FR, van der Meer FJ. Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost 2009; 101 (03) 552-556
• 9 Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2 (06) 591-597
• 10 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
• 11 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 12 Granger CB, Alexander JH, McMurray JJV. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 13 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 14 Weitz JI, Semchuk W, Turpie AG. , et al. Trends in prescribing oral anticoagulants in Canada, 2008-2014. Clin Ther 2015; 37 (11) 2506-2514
• 15 Lip GY, Laroche C, Dan GA. , et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16 (03) 308-319
• 16 Eikelboom JW, Connolly SJ, Brueckmann M. , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
• 17 Krijthe BP, Kunst A, Benjamin EJ. , et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34 (35) 2746-2751
• 18 Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279 (09) 657-662
• 19 Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130 (05) 1390-1396
• 20 Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135 (06) 393-400
• 21 Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med 2004; 164 (14) 1557-1560
• 22 Hwang JM, Taylor TN, Sharma KP, Clemente JL, Garwood CL. Bridging for an isolated subtherapeutic INR: an evaluation of clinical practice patterns, outcomes, and costs from an anticoagulation clinic. J Thromb Thrombolysis 2012; 33 (01) 28-37
• 23 Prochaska JH, Göbel S, Keller K. , et al. e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study. J Thromb Haemost 2017; 15 (07) 1375-1385
• 24 Prochaska JH, Coldewey M, Göbel S. , et al; thrombEVAL Study Group. Evaluation of oral anticoagulation therapy: rationale and design of the thrombEVAL study programme. Eur J Prev Cardiol 2015; 22 (05) 622-628
• 25 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69 (03) 236-239
• 26 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87 (01) 4-14
• 27 Chugh SS, Havmoeller R, Narayanan K. , et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129 (08) 837-847
• 28 O'Byrne S, Barry MG, Collins WC, O'Connor P, Cullen MJ, Feely J. Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus. Clin Pharmacokinet 1993; 24 (02) 183-186
• 29 Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest 2013; 144 (05) 1555-1563
• 30 White HD, Gruber M, Feyzi J. , et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167 (03) 239-245
• 31 Ashburner JM, Go AS, Chang Y. , et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA Study. J Am Coll Cardiol 2016; 67 (03) 239-247
• 32 Banerjee C, Moon YP, Paik MC. , et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke 2012; 43 (05) 1212-1217
• 33 Janghorbani M, Hu FB, Willett WC. , et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care 2007; 30 (07) 1730-1735
• 34 Tani Y, Kondo N, Takagi D. , et al. Combined effects of eating alone and living alone on unhealthy dietary behaviors, obesity and underweight in older Japanese adults: results of the JAGES. Appetite 2015; 95: 1-8
• 35 Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116 (10) 651-656
• 36 Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93 (05) 872-875
• 37 Pulkki-Råback L, Kivimäki M, Ahola K. , et al. Living alone and antidepressant medication use: a prospective study in a working-age population. BMC Public Health 2012; 12: 236
• 38 Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 2012; 60 (08) 1487-1492
• 39 Reeves MJ, Prager M, Fang J, Stamplecoski M, Kapral MK. Impact of living alone on the care and outcomes of patients with acute stroke. Stroke 2014; 45 (10) 3083-3085
• 40 Shaffer JA, Thompson JL, Cheng B. , et al; WARCEF Investigators. Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. Int J Cardiol 2014; 177 (02) 715-717
• 41 Michal M, Prochaska JH, Keller K. , et al. Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: Results from the thrombEVAL study program. Int J Cardiol 2015; 187: 614-619
• 42 Michal M, Prochaska JH, Ullmann A. , et al. Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program. J Thromb Haemost 2014; 12 (12) 2024-2033
• 43 Witt DM, Delate T, Clark NP. , et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res 2013; 132 (02) e124-e130
• 44 Rose AJ, Miller DR, Ozonoff A. , et al. Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest 2013; 143 (03) 751-757
• 45 Garcia-Alamino JM, Ward AM, Alonso-Coello P. , et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010; (04) CD003839
• 46 Wan Y, Heneghan C, Perera R. , et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1 (02) 84-91
• 47 Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes 2011; 4 (03) 276-282
• 48 Ruiz-Ortiz M, Bertomeu V, Cequier Á, Marín F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114 (04) 695-701
• 49 Roldán V, Cancio S, Gálvez J. , et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective ‘real-world’ inception cohort study. Am J Med 2015; 128 (11) 1237-1243
• 50 Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015; 1 (03) 150-152
• 51 Bansilal S, Bloomgarden Z, Halperin JL. , et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 2015; 170 (04) 675-682
• 52 van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest 2006; 129 (05) 1155-1166